The damage-response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases

Journal of Infectious Diseases

Volumn 218, Issue , 2018, Pages S7-S11

  Pirofski, Liise Anne ^a   Casadevall, Arturo ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

damage response framework; host; infectious diseases; inflammation; microbe; microbial pathogenesis

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL MEDICINE; CONCEPTUAL FRAMEWORK; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DAMAGE RESPONSE FRAMEWORK; EBOLA HEMORRHAGIC FEVER; ELECTRONIC HEALTH RECORD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; INFLUENZA; MEDICAL EDUCATION; NONHUMAN; PATHOGENESIS; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; REITER SYNDROME; RHEUMATIC HEART DISEASE; SCIENTIST; SEVERE ACUTE RESPIRATORY SYNDROME; COMMUNICABLE DISEASE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATION; MICROBIOLOGY; PATHOLOGY; PERSONNEL;

ALLERGY AND IMMUNOLOGY; COMMUNICABLE DISEASES; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; MICROBIOLOGY; PHYSICIANS; RESEARCH PERSONNEL;

EID: 85055844574     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy083     Document Type: Article

References (52)

1. Casadevall A, Pirofski LA. Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity. Infect Immun 1999; 67:3703-13.
2. Casadevall A, Pirofski LA. What is a host? II: The attributes of individual susceptibility. Infect Immun February 2018; 86(2):e00636-17.
3. Casadevall A, Pirofski L. Host-pathogen interactions: The attributes of virulence. J Infect Dis 2001; 184:337-44.
4. Casadevall A, Pirofski LA. What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun 2015; 83:2-7.
5. Casadevall A, Pirofski LA. Accidental virulence, cryptic pathogenesis, martians, lost hosts, and the pathogenicity of environmental microbes. Eukaryot Cell 2007; 6:2169-74.
6. Pirofski LA, Casadevall A. What is infectiveness and how is it involved in infection and immunity? BMC Immunol 2015; 16:13.
7. Lang ZW, Zhang LJ, Zhang SJ, et al. A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology 2003; 35:526-31.
8. Kobasa D, Jones SM, Shinya K, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007; 445:319-23.
9. Loo YM, Gale M Jr. Influenza: Fatal immunity and the 1918 virus. Nature 2007; 445:267-8.
10. Dunst J, Kamena F, Matuschewski K. Cytokines and chemokines in cerebral malaria pathogenesis. Front Cell Infect Microbiol 2017; 7:324.
11. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 2013; 8:411-40.
12. Srikiatkhachorn A, Mathew A, Rothman AL. Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol 2017; 39:563-74.
13. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016; 13:3-10.
14. Misasi J, Sullivan NJ. Camouflage and misdirection: The full-on assault of Ebola virus disease. Cell 2014; 159:477-86.
15. Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from pandemic influenza. J Theor Biol 2011; 288:29-34.
16. Ferguson NM, Rodriguez-Barraquer I, Dorigatti I, Mier-Y-Teran-Romero L, Laydon DJ, Cummings DA. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science 2016; 353:1033-6.
17. Whitehead SS, Durbin AP, Pierce KK, et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis 2017; 11:e0005584.
18. Rana A, Ahmed M, Rub A, Akhter Y. A tug-of-war between the host and the pathogen generates strategic hotspots for the development of novel therapeutic interventions against infectious diseases. Virulence 2015; 6:566-80.
19. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: A systematic review. J Infect 2011; 63:187-99.
20. Fedson DS. Treating the host response to emerging virus diseases: Lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med 2016; 4:421.
21. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-? immunotherapy for the treatment of HIV-associated cryptococcal meningitis: A randomized controlled trial. AIDS 2012; 26:1105-13.
22. Beardsley J, Wolbers M, Kibengo FM, et al. CryptoDex Investigators. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med 2016; 374:542-54.
23. Casadevall A, Pirofski L. Immune-mediated damage completes the parabola: Cryptococcus neoformans pathogenesis can reflect the outcome of a weak or strong immune response. MBio November/December 2017; 8(6):e02063-17.
24. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-701.
25. Singh N, Lortholary O, Alexander BD, et al. Cryptococcal Collaborative Transplant Study Group. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40:1756-61.
26. Meya DB, Manabe YC, Boulware DR, Janoff EN. The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: Understanding a conundrum. Curr Opin Infect Dis 2016; 29:10-22.
27. Panackal AA, Wuest SC, Lin YC, et al. Paradoxical immune responses in non-HIV cryptococcal meningitis. PLoS Pathog 2015; 11:e1004884.
28. Kessler A, Dankwa S, Bernabeu M, et al. Linking EPCR-binding PfEMP1 to brain swelling in pediatric cerebral malaria. Cell Host Microbe 2017; 22:601-14.e5.
29. Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. J Infect Dis 2015; 211:1597-606.
30. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202:962-70.
31. Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS 2013; 27:2089-99.
32. Akilimali NA, Chang CC, Muema DM, et al. Plasma but not cerebrospinal fluid interleukin 7 and interleukin 5 levels pre-antiretroviral therapy commencement predict cryptococcosis-associated immune reconstitution inflammatory syndrome. Clin Infect Dis 2017; 65:1551-9.
33. Subramaniam K, Metzger B, Hanau LH, et al. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis 2009; 200:244-51.
34. Fedson DS. Pandemic influenza: A potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43:199-205.
35. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: A population-based, nested case-control study. Pharmacotherapy 2007; 27:325-32.
36. Fedson DS, Jacobson JR, Rordam OM, Opal SM. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. MBio 2015; 6:e00716.
37. Doshi SM, Kulkarni PA, Liao JM, Rueda AM, Musher DM. The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013; 345(3):173-7.
38. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of statins on influenza vaccine response in elderly individuals. J Infect Dis 2016; 213:1224-8.
39. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. J Infect Dis 2016; 213:1216-23.
40. Buchwald UK, Pirofski L. Immune therapy for infectious diseases at the dawn of the 21st century: The past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr Pharm Des 2003; 9:945-68.
41. Nielsen TB, Pantapalangkoor P, Luna BM, et al. Monoclonal antibody protects against Acinetobacter baumannii infection by enhancing bacterial clearance and evading sepsis. J Infect Dis 2017; 216:489-501.
42. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol 2007; 96:179-204.
43. Fabrizio K, Groner A, Boes M, Pirofski LA. A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol 2007; 14:382-90.
44. Tian H, Weber S, Thorkildson P, Kozel TR, Pirofski LA. Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun 2009; 77:1502-13.
45. Weber S, Tian H, van Rooijen N, Pirofski LA. A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fc? receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice. Infect Immun 2012; 80:1314-22.
46. Burns T, Abadi M, Pirofski LA. Modulation of the lung inflammatory response to serotype 8 pneumococcus infection by a human monoclonal IgM to serotype 8 capsular polysaccharide. Infect Immun 2005; 73:4530-8.
47. Casadevall A, Pirofski LA. A new synthesis for antibody-mediated immunity. Nat Immunol 2012; 13:21-8.
48. McClelland EE, Nicola AM, Prados-Rosales R, Casadevall A. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest 2010; 120:1355-61.
49. Yano M, Gohil S, Coleman JR, Manix C, Pirofski LA. Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing. mBio 2011 Nov 1; 2(5). pii: E00176-11. doi: 10.1128/mBio.00176-11.
50. Prados-Rosales R, Carreno L, Cheng T, et al. Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. PLoS Pathog 2017; 13:e1006250.
51. Rachini A, Pietrella D, Lupo P, et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 2007; 75:5085-94.
52. Panackal AA, Williamson KC, van de Beek D, Boulware DR, Williamson PR. Fighting the monster: Applying the host damage framework to human central nervous system infections. MBio 2016; 7:e01906-15.